Elsevier will conduct a data-driven analysis to help identify what works well in U.S. cancer research and what areas are more challenging. The report will help measure the frequency and value of interdisciplinary collaborations and identify centers of expertise. Elsevier expects to complete the report this fall, in the hopes it can equip the Moonshot Task Force with the information it needs to make informed decisions about research investments.
“Cancer is a large, diverse and consistently expanding disease. There have been significant breakthroughs, but cancer itself is continually evolving which makes it extremely challenging to assess where the opportunities and challenges lie,” Brad Fenwick, PhD, Elsevier’s senior vice president for global alliances and project lead, said in a statement. “The first critical step on any journey is to know where you are. For the National Cancer Moonshot Initiative, we’ll be providing an outline of the current state of cancer research relative to the areas of focus, as well as impact derived from the large data sets and research collaborations. Ultimately the report will provide a pathway to the most promising outcomes that will affect the greatest number of people.”
More articles on quality and infection control:
Lab-tested diagnosis needed for patients with long-term diarrhea, researcher says
CDC warns US hospitals of emerging, deadly yeast infection: 7 things to know
Zika prompts world’s top golfer to skip Olympics
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
